Q: What is Tecentriq used for?

Tecentriq is used to treat the following conditions: Hepatocellular carcinoma Non-small cell lung cancer Small cell lung cancer Others

Q: What are the active ingredients in Tecentriq?

The active ingredient in Tecentriq is atezolizumab .

Q: What are the side effects of Tecentriq?

Common side effects of Tecentriq may include: Fatigue Decreased appetite Nausea and others. Always consult with a healthcare professional about potential side effects.

Q: What drug class is Tecentriq?

Tecentriq belongs to the PD-L1 inhibitor drug class.

Q: What is the dosage of Tecentriq and how do I take it?

Administration Method Tecentriq is given by a healthcare provider in a hospital or clinic setting. It is available in two forms: Intravenous (IV) Infusion: The medication is delivered slowly into a vein. The first infusion usually takes about 60 minutes. If the first dose is well-tolerated, subsequent infusions may be shorter, often lasting about 30 minutes. Subcutaneous Injection: In some cases, the medication may be injected under the skin, typically in the thigh area. This process usually takes a few minutes. Dosing Schedule The frequency of treatments depends on the specific condition being treated and the formulation used. It is commonly administered once every two, three, or four weeks. Your healthcare provider will determine the appropriate schedule for your treatment plan. Missed Doses If you miss an appointment for a Tecentriq dose, contact your healthcare provider as soon as possible to reschedule. It is important to receive the medication on the schedule prescribed by your doctor to ensure the treatment is effective.

Q: Is Tecentriq safe during pregnancy and breastfeeding?

Pregnancy Tecentriq can cause fetal harm when administered to a pregnant woman. Based on how the drug works, it may cause the mother's immune system to respond against the developing fetus, which could lead to pregnancy loss or fetal death. Animal studies have shown that similar medications increase the risk of spontaneous abortion. Healthcare providers typically require a pregnancy test before starting treatment for individuals who can become pregnant. If you are pregnant or planning to become pregnant, it is important to discuss the potential risks to the fetus with your medical team. Contraception: Individuals of reproductive potential are advised to use effective birth control during treatment with Tecentriq and for at least 5 months after the final dose. Breastfeeding It is not known if Tecentriq passes into human breast milk. Because of the potential for serious adverse reactions in a nursing infant, manufacturers recommend that individuals do not breastfeed during treatment and for at least 5 months after the last dose. You should discuss feeding options with your healthcare provider to determine the safest approach for your situation.

Q: What forms and strengths does Tecentriq come in?

Available Forms Tecentriq is supplied as a sterile, preservative-free solution for administration by a healthcare professional. It is available in the following form: Intravenous Injection: A clear, colorless to slightly yellow liquid solution provided in single-dose vials. This medication is intended for dilution and administration as an infusion into a vein.

Q: What is the FDA approval status of Tecentriq?

FDA Approval and Indications Tecentriq is a programmed death-ligand 1 (PD-L1) blocking antibody. It is approved by the U.S. Food and Drug Administration (FDA) for the treatment of several malignancies, often depending on specific genetic markers or the stage of the disease. Key approved uses include: Non-Small Cell Lung Cancer (NSCLC): Approved as an adjuvant treatment following surgery and platinum-based chemotherapy for adults with Stage II to IIIA NSCLC whose tumors have PD-L1 expression on 1% or more of tumor cells. It is also approved for the first-line treatment of metastatic NSCLC in patients with high PD-L1 expression and no EGFR or ALK genomic tumor aberrations. Small Cell Lung Cancer (SCLC): Approved for use in combination with carboplatin and etoposide for the first-line treatment of adults with extensive-stage SCLC. Hepatocellular Carcinoma (HCC): Approved in combination with bevacizumab for patients with unresectable or metastatic HCC who have not received prior systemic therapy. Melanoma: Approved in combination with cobimetinib and vemurafenib for the treatment of patients with BRAF V600 mutation-positive unresectable or metastatic melanoma. Regulatory History and Safety The regulatory status of Tecentriq has evolved over time. Some indications that received accelerated approval, such as for certain types of urothelial (bladder) cancer, were later voluntarily withdrawn by the manufacturer after confirmatory trials did not meet their primary endpoints. There are currently no boxed warnings or Risk Evaluation and Mitigation Strategy (REMS) requirements for Tecentriq. However, the FDA monitors the drug for immune-related adverse reactions, which are a known risk with this class of immunotherapy.

Question 1

What is Tecentriq?

Accepted Answer

Tecentriq is a monoclonal antibody known as a programmed death-ligand 1 (PD-L1) blocking agent. It works by binding to the PD-L1 protein found on some cancer cells and immune cells, which prevents the protein from interacting with receptors that normally keep the immune system in check.

By blocking this interaction, the medication helps the body's immune system identify and attack cancer cells more effectively. This type of therapy is designed to enhance the natural ability of the immune system to recognize and destroy abnormal cells.

Question 2

What is Tecentriq used for?

Accepted Answer

Tecentriq is used to treat the following conditions:

Hepatocellular carcinoma
Non-small cell lung cancer
Small cell lung cancer
Others

Question 3

How does Tecentriq work?

Accepted Answer

The immune system uses specialized white blood cells called T-cells to protect the body from infections and abnormal cells, including cancer. However, some cancer cells develop ways to hide from these T-cells to avoid being destroyed.

Tecentriq (atezolizumab) is a monoclonal antibody that targets a specific protein called programmed death-ligand 1 (PD-L1). This protein can be found on the surface of some cancer cells and certain immune cells.

When PD-L1 binds to other proteins (PD-1 and B7.1) on the surface of T-cells, it acts like a brake, sending a signal that tells the T-cell not to attack. Tecentriq works by:

Blocking the PD-L1 protein: By attaching to PD-L1, the drug prevents it from connecting with the receptors on T-cells.
Releasing the brakes: Once the interaction is blocked, the immune system's brakes are released.
Activating T-cells: This allows the T-cells to recognize the cancer cells as a threat and begin attacking them.

Because Tecentriq works with the immune system rather than attacking the cancer directly, it is classified as an immunotherapy or a checkpoint inhibitor.

Question 4

What are the active ingredients in Tecentriq?

Accepted Answer

The active ingredient in Tecentriq is atezolizumab.

Question 5

What are the side effects of Tecentriq?

Accepted Answer

Common side effects of Tecentriq may include:

Fatigue
Decreased appetite
Nausea
and others.

Always consult with a healthcare professional about potential side effects.

Question 6

What drug class is Tecentriq?

Accepted Answer

Tecentriq belongs to the PD-L1 inhibitor drug class.

Question 7

What is the dosage of Tecentriq and how do I take it?

Accepted Answer

Administration Method

Tecentriq is given by a healthcare provider in a hospital or clinic setting. It is available in two forms:

Intravenous (IV) Infusion: The medication is delivered slowly into a vein. The first infusion usually takes about 60 minutes. If the first dose is well-tolerated, subsequent infusions may be shorter, often lasting about 30 minutes.
Subcutaneous Injection: In some cases, the medication may be injected under the skin, typically in the thigh area. This process usually takes a few minutes.

Dosing Schedule

The frequency of treatments depends on the specific condition being treated and the formulation used. It is commonly administered once every two, three, or four weeks. Your healthcare provider will determine the appropriate schedule for your treatment plan.

Missed Doses

If you miss an appointment for a Tecentriq dose, contact your healthcare provider as soon as possible to reschedule. It is important to receive the medication on the schedule prescribed by your doctor to ensure the treatment is effective.

Question 8

Is Tecentriq safe during pregnancy and breastfeeding?

Accepted Answer

Pregnancy

Tecentriq can cause fetal harm when administered to a pregnant woman. Based on how the drug works, it may cause the mother's immune system to respond against the developing fetus, which could lead to pregnancy loss or fetal death. Animal studies have shown that similar medications increase the risk of spontaneous abortion.

Healthcare providers typically require a pregnancy test before starting treatment for individuals who can become pregnant. If you are pregnant or planning to become pregnant, it is important to discuss the potential risks to the fetus with your medical team.

Contraception: Individuals of reproductive potential are advised to use effective birth control during treatment with Tecentriq and for at least 5 months after the final dose.

Breastfeeding

It is not known if Tecentriq passes into human breast milk. Because of the potential for serious adverse reactions in a nursing infant, manufacturers recommend that individuals do not breastfeed during treatment and for at least 5 months after the last dose. You should discuss feeding options with your healthcare provider to determine the safest approach for your situation.

Question 9

What forms and strengths does Tecentriq come in?

Accepted Answer

Available Forms

Tecentriq is supplied as a sterile, preservative-free solution for administration by a healthcare professional. It is available in the following form:

Intravenous Injection: A clear, colorless to slightly yellow liquid solution provided in single-dose vials. This medication is intended for dilution and administration as an infusion into a vein.

Question 10

What is the FDA approval status of Tecentriq?

Accepted Answer

FDA Approval and Indications

Tecentriq is a programmed death-ligand 1 (PD-L1) blocking antibody. It is approved by the U.S. Food and Drug Administration (FDA) for the treatment of several malignancies, often depending on specific genetic markers or the stage of the disease. Key approved uses include:

Non-Small Cell Lung Cancer (NSCLC): Approved as an adjuvant treatment following surgery and platinum-based chemotherapy for adults with Stage II to IIIA NSCLC whose tumors have PD-L1 expression on 1% or more of tumor cells. It is also approved for the first-line treatment of metastatic NSCLC in patients with high PD-L1 expression and no EGFR or ALK genomic tumor aberrations.
Small Cell Lung Cancer (SCLC): Approved for use in combination with carboplatin and etoposide for the first-line treatment of adults with extensive-stage SCLC.
Hepatocellular Carcinoma (HCC): Approved in combination with bevacizumab for patients with unresectable or metastatic HCC who have not received prior systemic therapy.
Melanoma: Approved in combination with cobimetinib and vemurafenib for the treatment of patients with BRAF V600 mutation-positive unresectable or metastatic melanoma.

Regulatory History and Safety

The regulatory status of Tecentriq has evolved over time. Some indications that received accelerated approval, such as for certain types of urothelial (bladder) cancer, were later voluntarily withdrawn by the manufacturer after confirmatory trials did not meet their primary endpoints.

There are currently no boxed warnings or Risk Evaluation and Mitigation Strategy (REMS) requirements for Tecentriq. However, the FDA monitors the drug for immune-related adverse reactions, which are a known risk with this class of immunotherapy.

Question 11

What should I know about Tecentriq and fda approval?

Accepted Answer

Initial and Subsequent Approvals

Tecentriq first received FDA approval in 2016. Since then, its approved uses have expanded to include various stages and types of cancer, often used when the cancer has spread or cannot be removed by surgery.

Approved Indications

The FDA has approved Tecentriq for the following conditions:

Non-Small Cell Lung Cancer (NSCLC): Used as a standalone treatment, in combination with other therapies, or as an adjuvant treatment after surgery and chemotherapy for certain patients.
Small Cell Lung Cancer (SCLC): Used in combination with chemotherapy as a first-line treatment for extensive-stage disease.
Hepatocellular Carcinoma: Used in combination with bevacizumab for patients with liver cancer that has spread or cannot be removed by surgery.
Melanoma: Used in combination with cobimetinib and vemurafenib for certain types of advanced skin cancer.
Alveolar Soft Part Sarcoma: Approved for adults and children 2 years of age and older with this rare type of cancer.

Some approvals were granted under the FDA's accelerated approval program, which allows for earlier access to medications that treat serious conditions based on promising initial data, though continued approval may depend on further clinical trials.

Tecentriq

📋Overview

How It Works

Uses

Active Ingredients

Common Side Effects

Warnings & Precautions

Dosage

Pregnancy & Breastfeeding

Frequently Asked Questions

📚References

Found an Error?

Find Discounts for Tecentriq

Hospitals.net Disclosure